We are analyzing https://link.springer.com/article/10.1007/s13402-019-00489-1.

Title:
The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches | Cellular Oncology
Description:
Background Breast cancer is the most prevalent cancer among women worldwide and the fifth cause of death among all cancer patients. Breast cancer development is driven by genetic and epigenetic alterations, with the tumor microenvironment (TME) playing an essential role in disease progression and evolution through mechanisms like inflammation promotion. TNF-α is one of the essential pro-inflammatory cytokines found in the TME of breast cancer patients, being secreted both by stromal cells, mainly by tumor-associated macrophages, and by the cancer cells themselves. In this review, we explore the biological and clinical impact of TNF-α in all stages of breast cancer development. First of all, we explore the correlation between TNF-α expression levels at the tumor site or in plasma/serum of breast cancer patients and their respective clinical status and outcome. Secondly, we emphasize the role of TNF-α signaling in both estrogen-positive and -negative breast cancer cells. Thirdly, we underline TNF-α involvement in epithelial-to-mesenchymal transition (EMT) and metastasis of breast cancer cells, and we point out the contribution of TNF-α to the development of acquired drug resistance. Conclusions Collectively, these data reveal a pro-tumorigenic role of TNF-α during breast cancer progression and metastasis. We systemize the knowledge regarding TNF-α-related therapies in breast cancer, and we explain how TNF-α may act as both a target and a drug in different breast cancer therapeutic approaches. By corroborating the known molecular effects of TNF-α signaling in breast cancer cells with the results from several preclinical and clinical trials, including TNF-α-related clinical observations, we conclude that the potential of TNF-α in breast cancer therapy promises to be of great interest.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

pubmed, cancer, google, scholar, article, cas, breast, tumor, cell, cells, central, necrosis, res, factor, tnfalpha, tnfα, expression, factoralpha, oncol, macrophages, patients, progression, metastasis, apoptosis, clinical, role, wang, biol, stem, nfkappab, lin, microenvironment, tumour, response, zhang, therapeutic, inflammation, therapy, gene, chen, growth, receptor, tnf, mcf, liu, transition, drug, access, clin, int,

Topics {✒️}

tnfalpha-induced epithelial-mesenchymal transition tumour necrosis factor-alpha tnf-alpha-treated mcf-7 cells colony-stimulating factor-1 pathway mitogen-activated protein kinase tumor necrosis factor-alpha triple-negative breast cancer month download article/chapter epithelial-mesenchymal transition induced tnf-alpha sensitizes chemotherapy mammary tumor-bearing mice tnf-alpha levels correlate tumour micro-environment heterogeneity endotoxin-induced serum factor cell cycle-related proteins tnf-α-related therapies nf-kappab-mediated inhibition platinum-induced fatty acids nf-kappab/hif1alpha axis tnf-alpha-induced apoptosis tnf-α expression levels tumor growth-promoting response ioana berindan-neagoe tumour necrosis factor pubmed google scholar underline tnf-α involvement article google scholar tnf-α gene knockout akt/nf-kappab pathway inflammation-induced cell migration tumor necrosis factor reciprocal tumor-microenvironment interactions bcrp/mxr/abcp gene small-cell lung cancer nf-kappab target genes nanobody potentiates paclitaxel-therapy epithelial-mesenchymal transition /p-stat3/hbxip/tnfr1 nf-kappab pathway nuclear factor kappab shigella mediated depletion nf-kappab correlate tnf-α signaling human breast cancer tnfr1/nf-kappab nf-kappab activation nuclear factor-kappa pro-tumorigenic role full article pdf breast carcinoma progression

Questions {❓}

Mantovani, Inflammation and cancer: Back to Virchow?
Wilson, Tumor necrosis factor: Renaissance as a cancer therapeutic?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches
         description:Breast cancer is the most prevalent cancer among women worldwide and the fifth cause of death among all cancer patients. Breast cancer development is driven by genetic and epigenetic alterations, with the tumor microenvironment (TME) playing an essential role in disease progression and evolution through mechanisms like inflammation promotion. TNF-α is one of the essential pro-inflammatory cytokines found in the TME of breast cancer patients, being secreted both by stromal cells, mainly by tumor-associated macrophages, and by the cancer cells themselves. In this review, we explore the biological and clinical impact of TNF-α in all stages of breast cancer development. First of all, we explore the correlation between TNF-α expression levels at the tumor site or in plasma/serum of breast cancer patients and their respective clinical status and outcome. Secondly, we emphasize the role of TNF-α signaling in both estrogen-positive and -negative breast cancer cells. Thirdly, we underline TNF-α involvement in epithelial-to-mesenchymal transition (EMT) and metastasis of breast cancer cells, and we point out the contribution of TNF-α to the development of acquired drug resistance. Collectively, these data reveal a pro-tumorigenic role of TNF-α during breast cancer progression and metastasis. We systemize the knowledge regarding TNF-α-related therapies in breast cancer, and we explain how TNF-α may act as both a target and a drug in different breast cancer therapeutic approaches. By corroborating the known molecular effects of TNF-α signaling in breast cancer cells with the results from several preclinical and clinical trials, including TNF-α-related clinical observations, we conclude that the potential of TNF-α in breast cancer therapy promises to be of great interest.
         datePublished:2020-01-03T00:00:00Z
         dateModified:2020-01-03T00:00:00Z
         pageStart:1
         pageEnd:18
         sameAs:https://doi.org/10.1007/s13402-019-00489-1
         keywords:
            Breast cancer
            TNF-α
            Inflammatory cytokine
            Proliferation
            Survival
            EMT
            Stem cell
            Metastasis
            Chemoresistance
            Cancer Research
            Biomedicine
            general
            Pathology
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13402-019-00489-1/MediaObjects/13402_2019_489_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13402-019-00489-1/MediaObjects/13402_2019_489_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13402-019-00489-1/MediaObjects/13402_2019_489_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13402-019-00489-1/MediaObjects/13402_2019_489_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13402-019-00489-1/MediaObjects/13402_2019_489_Fig5_HTML.png
         isPartOf:
            name:Cellular Oncology
            issn:
               2211-3436
               2211-3428
            volumeNumber:43
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Netherlands
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Daniel Cruceriu
               affiliation:
                     name:The Oncology Institute “Prof. Dr. Ion Chiricuta”
                     address:
                        name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
                        type:PostalAddress
                     type:Organization
                     name:“Babes-Bolyai” University
                     address:
                        name:Department of Molecular Biology and Biotechnology, “Babes-Bolyai” University, Cluj-Napoca, Romania
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Oana Baldasici
               affiliation:
                     name:The Oncology Institute “Prof. Dr. Ion Chiricuta”
                     address:
                        name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ovidiu Balacescu
               url:http://orcid.org/0000-0003-0253-7103
               affiliation:
                     name:The Oncology Institute “Prof. Dr. Ion Chiricuta”
                     address:
                        name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
                        type:PostalAddress
                     type:Organization
                     name:“Iuliu Hatieganu” University of Medicine and Pharmacy
                     address:
                        name:11th Department of Medical Oncology, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Ioana Berindan-Neagoe
               affiliation:
                     name:The Oncology Institute “Prof. Dr. Ion Chiricuta”
                     address:
                        name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
                        type:PostalAddress
                     type:Organization
                     name:“Iuliu Hatieganu” University of Medicine and Pharmacy
                     address:
                        name:Research Center for Functional Genomics, Biomedicine and Translational Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
                        type:PostalAddress
                     type:Organization
                     name:“Iuliu Hatieganu” University of Medicine and Pharmacy
                     address:
                        name:MedFuture Research Center for Advanced Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches
      description:Breast cancer is the most prevalent cancer among women worldwide and the fifth cause of death among all cancer patients. Breast cancer development is driven by genetic and epigenetic alterations, with the tumor microenvironment (TME) playing an essential role in disease progression and evolution through mechanisms like inflammation promotion. TNF-α is one of the essential pro-inflammatory cytokines found in the TME of breast cancer patients, being secreted both by stromal cells, mainly by tumor-associated macrophages, and by the cancer cells themselves. In this review, we explore the biological and clinical impact of TNF-α in all stages of breast cancer development. First of all, we explore the correlation between TNF-α expression levels at the tumor site or in plasma/serum of breast cancer patients and their respective clinical status and outcome. Secondly, we emphasize the role of TNF-α signaling in both estrogen-positive and -negative breast cancer cells. Thirdly, we underline TNF-α involvement in epithelial-to-mesenchymal transition (EMT) and metastasis of breast cancer cells, and we point out the contribution of TNF-α to the development of acquired drug resistance. Collectively, these data reveal a pro-tumorigenic role of TNF-α during breast cancer progression and metastasis. We systemize the knowledge regarding TNF-α-related therapies in breast cancer, and we explain how TNF-α may act as both a target and a drug in different breast cancer therapeutic approaches. By corroborating the known molecular effects of TNF-α signaling in breast cancer cells with the results from several preclinical and clinical trials, including TNF-α-related clinical observations, we conclude that the potential of TNF-α in breast cancer therapy promises to be of great interest.
      datePublished:2020-01-03T00:00:00Z
      dateModified:2020-01-03T00:00:00Z
      pageStart:1
      pageEnd:18
      sameAs:https://doi.org/10.1007/s13402-019-00489-1
      keywords:
         Breast cancer
         TNF-α
         Inflammatory cytokine
         Proliferation
         Survival
         EMT
         Stem cell
         Metastasis
         Chemoresistance
         Cancer Research
         Biomedicine
         general
         Pathology
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13402-019-00489-1/MediaObjects/13402_2019_489_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13402-019-00489-1/MediaObjects/13402_2019_489_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13402-019-00489-1/MediaObjects/13402_2019_489_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13402-019-00489-1/MediaObjects/13402_2019_489_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13402-019-00489-1/MediaObjects/13402_2019_489_Fig5_HTML.png
      isPartOf:
         name:Cellular Oncology
         issn:
            2211-3436
            2211-3428
         volumeNumber:43
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Netherlands
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Daniel Cruceriu
            affiliation:
                  name:The Oncology Institute “Prof. Dr. Ion Chiricuta”
                  address:
                     name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
                     type:PostalAddress
                  type:Organization
                  name:“Babes-Bolyai” University
                  address:
                     name:Department of Molecular Biology and Biotechnology, “Babes-Bolyai” University, Cluj-Napoca, Romania
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Oana Baldasici
            affiliation:
                  name:The Oncology Institute “Prof. Dr. Ion Chiricuta”
                  address:
                     name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ovidiu Balacescu
            url:http://orcid.org/0000-0003-0253-7103
            affiliation:
                  name:The Oncology Institute “Prof. Dr. Ion Chiricuta”
                  address:
                     name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
                     type:PostalAddress
                  type:Organization
                  name:“Iuliu Hatieganu” University of Medicine and Pharmacy
                  address:
                     name:11th Department of Medical Oncology, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Ioana Berindan-Neagoe
            affiliation:
                  name:The Oncology Institute “Prof. Dr. Ion Chiricuta”
                  address:
                     name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
                     type:PostalAddress
                  type:Organization
                  name:“Iuliu Hatieganu” University of Medicine and Pharmacy
                  address:
                     name:Research Center for Functional Genomics, Biomedicine and Translational Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
                     type:PostalAddress
                  type:Organization
                  name:“Iuliu Hatieganu” University of Medicine and Pharmacy
                  address:
                     name:MedFuture Research Center for Advanced Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cellular Oncology
      issn:
         2211-3436
         2211-3428
      volumeNumber:43
Organization:
      name:Springer Netherlands
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The Oncology Institute “Prof. Dr. Ion Chiricuta”
      address:
         name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
         type:PostalAddress
      name:“Babes-Bolyai” University
      address:
         name:Department of Molecular Biology and Biotechnology, “Babes-Bolyai” University, Cluj-Napoca, Romania
         type:PostalAddress
      name:The Oncology Institute “Prof. Dr. Ion Chiricuta”
      address:
         name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
         type:PostalAddress
      name:The Oncology Institute “Prof. Dr. Ion Chiricuta”
      address:
         name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
         type:PostalAddress
      name:“Iuliu Hatieganu” University of Medicine and Pharmacy
      address:
         name:11th Department of Medical Oncology, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
         type:PostalAddress
      name:The Oncology Institute “Prof. Dr. Ion Chiricuta”
      address:
         name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
         type:PostalAddress
      name:“Iuliu Hatieganu” University of Medicine and Pharmacy
      address:
         name:Research Center for Functional Genomics, Biomedicine and Translational Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
         type:PostalAddress
      name:“Iuliu Hatieganu” University of Medicine and Pharmacy
      address:
         name:MedFuture Research Center for Advanced Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Daniel Cruceriu
      affiliation:
            name:The Oncology Institute “Prof. Dr. Ion Chiricuta”
            address:
               name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
               type:PostalAddress
            type:Organization
            name:“Babes-Bolyai” University
            address:
               name:Department of Molecular Biology and Biotechnology, “Babes-Bolyai” University, Cluj-Napoca, Romania
               type:PostalAddress
            type:Organization
      name:Oana Baldasici
      affiliation:
            name:The Oncology Institute “Prof. Dr. Ion Chiricuta”
            address:
               name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
               type:PostalAddress
            type:Organization
      name:Ovidiu Balacescu
      url:http://orcid.org/0000-0003-0253-7103
      affiliation:
            name:The Oncology Institute “Prof. Dr. Ion Chiricuta”
            address:
               name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
               type:PostalAddress
            type:Organization
            name:“Iuliu Hatieganu” University of Medicine and Pharmacy
            address:
               name:11th Department of Medical Oncology, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Ioana Berindan-Neagoe
      affiliation:
            name:The Oncology Institute “Prof. Dr. Ion Chiricuta”
            address:
               name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
               type:PostalAddress
            type:Organization
            name:“Iuliu Hatieganu” University of Medicine and Pharmacy
            address:
               name:Research Center for Functional Genomics, Biomedicine and Translational Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
               type:PostalAddress
            type:Organization
            name:“Iuliu Hatieganu” University of Medicine and Pharmacy
            address:
               name:MedFuture Research Center for Advanced Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
      name:Department of Molecular Biology and Biotechnology, “Babes-Bolyai” University, Cluj-Napoca, Romania
      name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
      name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
      name:11th Department of Medical Oncology, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
      name:Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
      name:Research Center for Functional Genomics, Biomedicine and Translational Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
      name:MedFuture Research Center for Advanced Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(435)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.44s.

LINK . SPRINGER . COM {}